Press releases
- Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
- Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank
- Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
- Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
More ▼
Key statistics
As of last trade Ryvu Therapeutics SA (9Y4:DEU) traded at 12.30, 9.24% above its 52-week low of 11.26, set on Apr 11, 2023.
52-week range
Open | 12.54 |
---|---|
High | 12.54 |
Low | 12.30 |
Bid | 12.48 |
Offer | 13.12 |
Previous close | 12.48 |
Average volume | 0.00 |
---|---|
Shares outstanding | 23.12m |
Free float | 16.31m |
P/E (TTM) | -- |
Market cap | 1.28bn PLN |
EPS (TTM) | -4.05 PLN |
Data delayed at least 15 minutes, as of Mar 28 2024 09:45 BST.
More ▼